KVA12123, a next-generation IgG1, binds VISTA across both pH environments, blocks interactions with multiple ligands (PSGL-1, VSIG3, VSIG8, LRIG1), and demonstrates strong receptor occupancy and anti-tumor efficacy with minimized FcγR engagement in Phase I/II studies [317]. The gene discussed is LRIG1; the disease is neoplasm.